<DOC>
	<DOCNO>NCT02473211</DOCNO>
	<brief_summary>For chronic hepatitis C patient , interferon-ineligible intolerant , burn need development pan-oral interferon-free regimen . The investigator examine efficacy safety sofosbuvir , NS5B nucleotide polymerase inhibitor daclatasvir , NS5A replication complex inhibitor Chinese treatment-experienced cirrhosis patient chronic G1b infection .</brief_summary>
	<brief_title>SOF Plus DCV Treating Chinese Treatment-experienced HCV Patients</brief_title>
	<detailed_description>Chinese genotype 1b HCV treatment-experienced cirrhotic patient recruit treated 12 week sofosbuvir 400 mg daily plus daclatasvir 60 mg daily . At baseline , liver stiffness measurement ( LSM ) use transient elastography ( FibroScan® ) use assess liver fibrosis single nucleotide polymorphism ofinterferon-λ 3 ( IL-28 , rs12979860 , C T ) IFLN4 ( ss469415590 , TT ΔG ) determine . Serial measurement plasma HCV RNA level perform use COBAS TaqMan real-time assay ( Roche version 2.0 ) , baseline , Day 2,4 7 , week 2,4 12 , post-treatment week 12 . The primary efficacy end point sustain virologic response 12 week end treatment ( SVR12 ) .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>1 . Patients chronically infect HCV Genotype1b ; 2 . Documented evidence relapse completion previous course interferonbased regimen without ribavirin ; 3 . HCV RNA level great 10,000 IU/ml screening ; 4 . Patients compensate cirrhosis permit . 1 . Current prior history : Clinicallysignificant illness ( HCV ) major medical disorder may interfere treatment , assessment compliance protocol ; individual currently evaluation potentially clinicallysignificant illness ( HCV ) also exclude ; 2 . Screening ECG clinically significant abnormality ; 3 . Laboratory result outside acceptable range screen ; 4 . Infection hepatitis B virus ( HBV ) human immunodeficiency virus ( HIV ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>